This is particularly relevant in AD, where subtle changes in CP volume and structure may reflect disease progression or therapeutic response, and its volume alterations in might implicate mechanistic and functional impairment (Cserr, 1971; Althubaity et al., 2022; Choi et al., 2022; Bouhrara et al., 2024; Bouhrara et al., 2024; Rmeily-Haddad et al., 2011). This evidence concerns the gene CP and Alzheimer disease.